|
1
|
Endo-Munoz L, Evdokiou A and Saunders NA:
The role of osteoclasts and tumour-associated macrophages in
osteosarcoma metastasis. Biochim Biophys Acta. 1826:434–442.
2012.PubMed/NCBI
|
|
2
|
Poletajew S, Fus L and Wasiutyński A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumors. Ortop Traumatol Rehabil. 13:537–545. 2011.
View Article : Google Scholar
|
|
3
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan
SC, Yang YJ and Gu ZP: Perifosine induces cell apoptosis in human
osteosarcoma cells: New implication for osteosarcoma therapy? Cell
Biochem Biophys. 65:217–227. 2013. View Article : Google Scholar
|
|
5
|
Chen ZJ and Sun LJ: Nonproteolytic
functions of ubiquitin in cell signaling. Mol Cell. 33:275–286.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Komander D: The emerging complexity of
protein ubiquitination. Biochem Soc Trans. 37:937–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fraile JM, Quesada V, Rodríguez D, Freije
JM and López-Otín C: Deubiquitinases in cancer: New functions and
therapeutic options. Oncogene. 31:2373–2388. 2012. View Article : Google Scholar
|
|
8
|
García-Santisteban I, Peters GJ,
Giovannetti E and Rodríguez JA: USP1 deubiquitinase: Cellular
functions, regulatory mechanisms and emerging potential as target
in cancer therapy. Mol Cancer. 12:912013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams SA, Maecker HL, French DM, Liu J,
Gregg A, Silverstein LB, Cao TC, Carano RA and Dixit VM: USP1
deubiquitinates ID proteins to preserve a mesenchymal stem cell
program in osteosarcoma. Cell. 146:918–930. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Luo X, Hu H, Wang R, Sun Y, Zeng R
and Chen H: Integrative proteomics and tissue microarray profiling
indicate the association between overexpressed serum proteins and
non-small cell lung cancer. PLoS One. 7:e517482012. View Article : Google Scholar
|
|
11
|
Kim H and D’Andrea AD: Regulation of DNA
cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev.
26:1393–1408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang TT, Nijman SM, Mirchandani KD,
Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R and
D’Andrea AD: Regulation of monoubiquitinated PCNA by DUB
autocleavage. Nat Cell Biol. 8:339–347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fox JT, Lee KY and Myung K: Dynamic
regulation of PCNA ubiquitylation/deubiquitylation. FEBS Lett.
585:2780–2785. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cohn MA, Kowal P, Yang K, Haas W, Huang
TT, Gygi SP and D’Andrea AD: A UAF1-containing multisubunit protein
complex regulates the Fanconi anemia pathway. Mol Cell. 28:786–797.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Villamil MA, Chen J, Liang Q and Zhuang Z:
A noncanonical cysteine protease USP1 is activated through active
site modulation by USP1-associated factor 1. Biochemistry.
51:2829–2839. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang K, Moldovan GL, Vinciguerra P, Murai
J, Takeda S and D’Andrea AD: Regulation of the Fanconi anemia
pathway by a SUMO-like delivery network. Genes Dev. 25:1847–1858.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Davidson BL and McCray PB Jr: Current
prospects for RNA interference-based therapies. Nat Rev Genet.
12:329–340. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Angaji SA, Hedayati SS, Poor RH, Madani S,
Poor SS and Panahi S: Application of RNA interference in treating
human diseases. J Genet. 89:527–537. 2010. View Article : Google Scholar
|
|
19
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fujiwara T, Saito A, Suzuki M, Shinomiya
H, Suzuki T, Takahashi E, Tanigami A, Ichiyama A, Chung CH,
Nakamura Y, et al: Identification and chromosomal assignment of
USP1, a novel gene encoding a human ubiquitin-specific protease.
Genomics. 54:155–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Békés M, Okamoto K, Crist SB, Jones MJ,
Chapman JR, Brasher BB, Melandri FD, Ueberheide BM, Denchi EL and
Huang TT: DUB-resistant ubiquitin to survey ubiquitination switches
in mammalian cells. Cell Rep. 5:826–838. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cohn MA, Kee Y, Haas W, Gygi SP and
D’Andrea AD: UAF1 is a subunit of multiple deubiquitinating enzyme
complexes. J Biol Chem. 284:5343–5351. 2009. View Article : Google Scholar :
|
|
23
|
Chen J, Dexheimer TS, Ai Y, Liang Q,
Villamil MA, Inglese J, Maloney DJ, Jadhav A, Simeonov A and Zhuang
Z: Selective and cell-active inhibitors of the USP1/UAF1
deubiquitinase complex reverse cisplatin resistance in non-small
cell lung cancer cells. Chem Biol. 18:1390–1400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang Q, Dexheimer TS, Zhang P, Rosenthal
AS, Villamil MA, You C, Zhang Q, Chen J, Ott CA, Sun H, et al: A
selective USP1-UAF1 inhibitor links deubiquitination to DNA damage
responses. Nat Chem Biol. 10:298–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wahi D, Jamal S, Goyal S, Singh A, Jain R,
Rana P and Grover A: Cheminformatics models based on machine
learning approaches for design of USP1/UAF1 abrogators as
anticancer agents. Syst Synth Biol. 9:33–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McClurg UL and Robson CN: Deubiquitinating
enzymes as oncotargets. Oncotarget. 6:9657–9668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
D’Arcy P and Linder S: Molecular pathways:
Translational potential of deubiquitinases as drug targets. Clin
Cancer Res. 20:3908–3914. 2014. View Article : Google Scholar
|
|
28
|
Park E, Kim JM, Primack B, Weinstock DM,
Moreau LA, Parmar K and D’Andrea AD: Inactivation of Uaf1 causes
defective homologous recombination and early embryonic lethality in
mice. Mol Cell Biol. 33:4360–4370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahmed AA, Lu Z, Jennings NB,
Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF,
Vivas-Mejia P, Lopez-Berestein G, et al; Australian Ovarian Cancer
Study Group. SIK2 is a centrosome kinase required for bipolar
mitotic spindle formation that provides a potential target for
therapy in ovarian cancer. Cancer Cell. 18:109–121. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bon H, Wadhwa K, Schreiner A, Osborne M,
Carroll T, Ramos-Montoya A, Ross-Adams H, Visser M, Hoffmann R,
Ahmed AA, et al: Salt-inducible kinase 2 regulates mitotic
progression and transcription in prostate cancer. Mol Cancer Res.
13:620–635. 2015. View Article : Google Scholar :
|
|
31
|
Jamart C, Raymackers JM, Li An G,
Deldicque L and Francaux M: Prevention of muscle disuse atrophy by
MG132 proteasome inhibitor. Muscle Nerve. 43:708–716. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aparna M, Rao L, Kunhikatta V and
Radhakrishnan R: The role of MMP-2 and MMP-9 as prognostic markers
in the early stages of tongue squamous cell carcinoma. J Oral
Pathol Med. 44:345–352. 2015. View Article : Google Scholar
|
|
33
|
Yang W, Li Q and Pan Z:
Sphingosine-1-phosphate promotes extravillous trophoblast cell
invasion by activating MEK/ERK/MMP-2 signaling pathways via
S1P/S1PR1 axis activation. PLoS One. 9:e1067252014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen SJ, Yao XD, Peng BO, Xu YF, Wang GC,
Huang J, Liu M and Zheng JH: Epigallocatechin-3-gallate inhibits
migration and invasion of human renal carcinoma cells by
downregulating matrix metalloproteinase-2 and matrix
metalloproteinase-9. Exp Ther Med. 11:1243–1248. 2016.PubMed/NCBI
|
|
35
|
Kotliarova S, Pastorino S, Kovell LC,
Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee
J, et al: Glycogen synthase kinase-3 inhibition induces glioma cell
death through c-MYC, nuclear factor-kappaB, and glucose regulation.
Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Salim T, Sjölander A and Sand-Dejmek J:
Nuclear expression of glycogen synthase kinase-3β and lack of
membranous β-catenin is correlated with poor survival in colon
cancer. Int J Cancer. 133:807–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang QL, Xie XB, Wang J, Chen Q, Han AJ,
Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase
kinase-3β, NF-κB signaling, and tumorigenesis of human
osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yao K, Xing HC, Wu B, Li Y, Liao AJ, Yang
W and Liu ZG: Effect of TIEG1 on apoptosis and expression of
Bcl-2/Bax and Pten in leukemic cell lines. Genet Mol Res.
14:1968–1974. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hwang HC and Clurman BE: Cyclin E in
normal and neoplastic cell cycles. Oncogene. 24:2776–2786. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Spruck CH, Won KA and Reed SI: Deregulated
cyclin E induces chromosome instability. Nature. 401:297–300. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hunt KK and Keyomarsi K: Cyclin E as a
prognostic and predictive marker in breast cancer. Semin Cancer
Biol. 15:319–326. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arcaroli JJ, Quackenbush KS, Purkey A,
Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song
EK, et al: Tumours with elevated levels of the Notch and Wnt
pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor,
in a preclinical colorectal explant model. Br J Cancer.
109:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Takebe N, Miele L, Harris PJ, Jeong W,
Bando H, Kahn M, Yang SX and Ivy SP: Targeting Notch, Hedgehog, and
Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin
Oncol. 12:445–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ranganathan P, Weaver KL and Capobianco
AJ: Notch signalling in solid tumours: A little bit of everything
but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hajimoradi M, Mohammad Hassan Z, Ebrahimi
M, Soleimani M, Bakhshi M, Firouzi J and Samani FS: STAT3 is
overactivated in gastric cancer stem-like cells. Cell J.
17:617–628. 2016.PubMed/NCBI
|
|
48
|
Shames DS, Girard L, Gao B, Sato M, Lewis
CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, et al: A
genome-wide screen for promoter methylation in lung cancer
identifies novel methylation markers for multiple malignancies.
PLoS Med. 3:e4862006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Syed Khaja AS, Dizeyi N, Kopparapu PK,
Anagnostaki L, Härkönen P and Persson JL: Cyclin A1 modulates the
expression of vascular endothelial growth factor and promotes
hormone-dependent growth and angiogenesis of breast cancer. PLoS
One. 8:e722102013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wegiel B, Bjartell A, Ekberg J, Gadaleanu
V, Brunhoff C and Persson JL: A role for cyclin A1 in mediating the
autocrine expression of vascular endothelial growth factor in
prostate cancer. Oncogene. 24:6385–6393. 2005.PubMed/NCBI
|
|
51
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
52
|
van Gijn ME, Daemen MJ, Smits JF and
Blankesteijn WM: The wnt-frizzled cascade in cardiovascular
disease. Cardiovasc Res. 55:16–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kim YM, Kim IH and Nam TJ: Capsosiphon
fulvescens glycoprotein inhibits AGS gastric cancer cell
proliferation by downregulating Wnt-1 signaling. Int J Oncol.
43:1395–1401. 2013.PubMed/NCBI
|
